Biotech had an approval week. Ultragenyx’s first-ever gene therapy for glycogen storage disease type Ia, Regeneron’s second-ever disease-modifying therapy for fibrodysplasia ossificans progressiva, and Amylyx’s blowout Phase 3 win in post-bariatric hypoglycemia landed within…
Biotech’s week traded distress for discipline: Sangamo’s bankruptcy auction let PTC Therapeutics pick up a near-approval Fabry gene therapy for a fraction of its original value, Bristol Myers Squibb banked the first-ever approval of…
Weekly Biotech Signal Review — Week of July 26-31, 2026.
Astellas has declined to exercise its option on AviadoBio’s AAV-based gene therapy program targeting frontotemporal dementia (FTD), but the program will continue through nonprofit funding support. The development highlights an alternative pathway for sustaining…
The RNA therapeutics field is approaching a key inflection point with the anticipated initiation of the first clinical trial of engineered transfer RNA (tRNA) therapy, led by emerging players such as Alltrna. This modality…
